tiprankstipranks
Exelixis price target raised to $38 from $37 at Piper Sandler
PremiumThe FlyExelixis price target raised to $38 from $37 at Piper Sandler
5d ago
Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
Premium
Ratings
Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
5d ago
Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments
Premium
Ratings
Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments
5d ago
Exelixis reports Q4 EPS 55c, consensus 49c
PremiumThe FlyExelixis reports Q4 EPS 55c, consensus 49c
5d ago
Exelixis backs FY25 revenue view of $2.15B-$2.25B, consensus $2.25B
Premium
The Fly
Exelixis backs FY25 revenue view of $2.15B-$2.25B, consensus $2.25B
5d ago
EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
8d ago
Exelixis downgraded to Perform from Outperform at Oppenheimer
PremiumThe FlyExelixis downgraded to Perform from Outperform at Oppenheimer
24d ago
Exelixis downgraded to Perform at Oppenheimer on zanzalintinib concerns
Premium
The Fly
Exelixis downgraded to Perform at Oppenheimer on zanzalintinib concerns
24d ago
Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
Premium
The Fly
Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
25d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100